Table 1.

The prognostic values of immune landscape markers in EC

Biomarker	Prognostic value
	Clinical survival	Tumor stage	Differentiation grade	Metastasis	Response to chemotherapy	Response to immunotherapy
MAGE-A11	− [63]	N/A	N/A	+ [63]	N/A	N/A
NY-ESO-1	N/A	N/A	N/A	N/A	N/A	Vaccination:− [24]
TMB	N/A	N/A	N/A	N/A	N/A	PD-1 inhibition: + [18]
MANA	N/A	N/A	N/A	N/A	N/A	PD-1 inhibition: + [18]
PD-L1	N/A	N/A	N/A	N/A	N/A	PD-1 inhibition: + [18]
PD-1	N/A	+ [67]	N/A	+ [67]	N/A	N/A
CTLA-4	− [28]	N/A	N/A	N/A	N/A	N/A
IDO1	− [32, 70]	N/A	N/A	N/A	− [68]	N/A
PD-L1 + IDO1	− [68, 69]	N/A	N/A	N/A	− [69]	N/A
VISTA	+ [27]	N/A	N/A	N/A	N/A	N/A
TGF-β	N/A	N/A	N/A	N/A	− [72]	N/A
TGF-β + IL-10	N/A	+ [71]	N/A	N/A	N/A	N/A
IL-6	N/A	N/A	N/A	N/A	− [50]	N/A
CD80 or CD86	N/A	− [71, 73]	− [71, 73]	N/A	N/A	N/A
CD1a+ cells	N/A	N/A	− [73]	N/A	N/A	N/A
CD8+ TILs	+ [75]	N/A	N/A	− [75]	+ [75]	N/A
CD8+/Foxp3+ ratio	+ [29]	N/A	N/A	N/A	N/A	N/A
CCL4highCCL20low	+ [52]	N/A	N/A	N/A	N/A	N/A
M2-like TAMs	− [48, 49]	N/A	N/A	N/A	N/A	N/A
MDSCs	N/A	+ [50, 51]	N/A	N/A	− [50]	N/A

+, positively correlated; −, negatively correlated; N/A not available

EC esophageal cancer, MAGE-A11 melanoma-associated antigen A11, NY-ESO-1 New York esophageal squamous cell carcinoma 1, TMB tumor mutation burden, MANA mutation-associated neoantigen, PD-L1 programmed death-ligand 1, PD-1 programmed cell death protein 1, CTLA-4 cytotoxic T lymphocyte-associated protein 4, IDO1 indoleamine 2,3-dioxygenase 1, TGF-β transforming growth factor-β, IL-10 interleukin-10, IL-6 interleukin-6, TILs tumor-infiltrating lymphocytes, TAM tumor-associated macrophage, MDSC myeloid-derived suppressor cell